VIDEO: Therapeutic drug monitoring improves IBD outcomes

SAN ANTONIO — In this video, Bincy P. Abraham, MD, MS, AGAF, FACG, Fondren Distinguished Professor in Inflammatory Bowel Disease from Houston Methodist and Weill Cornell Medical College, reviews highlights from her presentation at the American College of Gastroenterology Meeting on therapeutic drug monitoring in patients with inflammatory bowel disease.Reactive therapeutic drug monitoring can be…

FDA approves Talicia for H. pylori infection in adults

The FDA approved Talicia for the treatment of Helicobacter pylori infection in adults, manufacturer Redhill Biopharma announced.H. pylori infection is the major cause of peptic ulcers and gastritis and is associated with an up to six-fold increased risk for gastric cancer and mucosal associated-lymphoid-type lymphoma, according to the CDC.Redhill said Talicia (omeprazole magnesium, amoxicillin and…

Namodenoson compassionate use program for HCC launches

Can-Fite BioPharma announced the initiation of a compassionate use program for Namodenoson to treat patients with hepatocellular carcinoma, according to a press release.The program is being administered by Salomon Stemmer, MD, principal investigator of the phase 2 study of Namodenoson from the Rabin Medical Center, Israel, and has started treating enrolled patients.“We are grateful to…

FDA hears testimony on enforcement discretion of FMT for C. diff

The FDA held a public comment session on Monday in Washington, D.C., to hear testimony on the agency’s policy on enforcement discretion of fecal microbiota transplantation for patients with recurrent Clostridioides difficile infection, as well as what is needed to make a path forward toward approval.Manufacturers, researchers, clinicians and patients were on hand to discuss…

Phase 3 trial of pancreatic cancer therapy misses primary endpoint

A phase 3 trial designed to assess an investigational drug for first-line treatment of metastatic pancreatic cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.Development of the agent — pegvorhyaluronidase alfa (PEGPH20, Halozyme Therapeutics) — will be discontinued.Pegvorhyaluronidase alfa is the pegylated version of rHuPH20, Halozyme’s proprietary recombinant human hyaluronidase…